Characterizing A Nasal Spray Formulation From Droplet To API Particle Size - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Characterizing A Nasal Spray Formulation From Droplet To API Particle Size
Regulatory guidance for nasal spray products recognises the effect on drug delivery of the particle size of both the delivered droplets and the suspended active. Here we examine the application of laser diffraction and automated image analysis combined with Raman spectroscopy in this context, highlighting the role these techniques can play in fast and efficient nasal spray characterisation.


Pharmaceutical Technology Europe
Volume 23, Issue 2

In conclusion

Laser diffraction and automated imaging combined with Raman spectroscopy are powerful, complementary techniques for nasal spray product characterisation. Laser diffraction measurements relate to the formulation in its entirety and support the development of formulation and device towards optimal dispersion. Laser diffraction studies are also required for routine quality control and to determine in vitro bioequivalence. In contrast, automated image analysis in combination with Raman spectroscopy enables particle size analysis of the API alone, an important variable with respect to bioavailiabilty. Both techniques are fast and efficient, with automated imaging offering substantial advantage — quicker measurement, better reproducibility — compared with manual microscopy. Together they promote the efficient commercialisation of new nasal spray products in accordance with the regulatory guidances.

Paul Kippax is Product Group Manager – Micrometrics, Malvern Instruments.

Deborah Huck is Product Technical Specialist – Morphological Imaging Systems, Malvern Instruments.

Carl Levoguer is Sales Specialist – Analytical Imaging Systems, Malvern Instruments.

Anne Virden is Product Technical Specialist – Diffraction, Malvern Instruments.

Julie Suman is President, NextBreath LLC.

References

1. FDA Guidance — Bioequivalance (BE) and bioavailability (BA) studies for nasal sprays and nasal aerosols for local action, April 2003.

2. P. Kippax, et al., Pharm. Technol. Eur., 22(9), 58–65 (2010).

Further reading

In the September 2010 issue of Pharmaceutical Technology Europe,2 the authors discuss in more detail the value of laser diffraction in helping formulators achieve optimal nasal spray product performance by enabling the capture of nasal droplet size data in real time.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here